Im­mat­ics re­ports more ear­ly-stage da­ta for melanoma cell ther­a­py with piv­otal tri­al un­der­way

Im­mat­ics has shared new sur­vival da­ta from a Phase 1b tri­al of its melanoma cell ther­a­py can­di­date, bol­ster­ing ex­pec­ta­tions for a reg­is­tra­tional study that it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER